Park Ha Biological Raises $1.8M in Deeply Discounted Private Placement, Adding to Dilution Concerns

summarizeSummary

Park Ha Biological Technology raised $1.8 million in a private placement at $0.18 per share — a 47% discount to the current price — with warrants for 2 million more shares. The deeply discounted deal underscores the company's urgent need for cash and adds to significant dilution risks.

check_boxKey Events · Financing and Capital Events · BYAH

• Deeply Discounted Private Placement

  At a 47% discount to the current $0.343 price, the company sold 10 million Class A ordinary shares at $0.18 each, raising $1.8 million in gross proceeds.

• Warrants Add to Dilution Overhang

  Investors received warrants to purchase 2 million additional shares at $0.18, exercisable for 5 years with no anti-dilution adjustments for stock splits.

• Cash Runway Remains Critical

  With only $918K in cash as of April 30, 2026, this raise provides minimal runway; the company continues to rely on dilutive financing to stay afloat.

• Follows Recent Dilutive Moves

  This placement comes after a $2 million offering in June 2026 and shareholder approval to increase authorized shares to 300 billion, highlighting ongoing dilution risk.

auto_awesomeAnalysis · BYAH · Industrial Applications And Services

A 47% discount to the current $0.343 price underscores the distress behind this $1.8 million raise, which came through the sale of 10 million shares at $0.18 each. The deal also includes warrants for 2 million more shares at the same price, with no anti-dilution protection for stock splits. This follows a $2 million offering in June and a recent shareholder vote authorizing up to 300 billion shares, signaling severe cash desperation. With only $918K in cash as of April 30, 2026, the company barely extends its runway. The deep discount and warrant structure are classic signs of distressed financing, likely to pressure the stock further.